Clinical trials: Essential Tremor
Essential Tremor
A Study to Evaluate SAGE-217 in Participants With Essential Tremor
This study is a three-part, multicenter, Phase 2a study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of SAGE-217 in adult participants with essential tremor.
- Trial name
- NCT02978781
- Testing
- SAGE-217
- Where
- 26 sites in United States
- Volunteers
- 34 people
- Sponsor
- Biogen
Essential Tremor
A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential Tremor
This is a phase 2, double-blind, placebo-controlled study to evaluate the safety and efficacy of SAGE-324 compared to placebo on upper limb (UL) tremor reduction in individuals with essential tremor (ET).
- Trial name
- NCT04305275
- Testing
- SAGE-324
- Where
- 27 sites in United States
- Volunteers
- 69 people
- Sponsor
- Sage Therapeutics
Essential Tremor
Prospective Study for Symptomatic Relief of ET With Cala Therapy
Prospective, multi-center, single-arm, non-significant risk study designed to evaluate the Cala TWO device. Subjects will be screened for eligibility and fitted with a Cala TWO device.
- Trial name
- PROSPECT (NCT03597100)
- Testing
- Cala TWO
- Where
- 32 sites in United States
- Volunteers
- 263 people
- Sponsor
- Cala Health, Inc.
Essential Tremor
Continued Access Protocol: ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Essential Tremors
The objective of this prospective, multi site, single-arm study is to capture the efficacy of treatment using the ExAblate Transcranial System and to further demonstrate safety in medication-refractory tremor in patients with…
- Trial name
- NCT02289560
- Testing
- Transcranial ExAblate
- Where
- 7 sites in United States
- Volunteers
- 61 people
- Sponsor
- InSightec
Essential Tremor
A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)
This is a 12-week, double-blind, placebo-controlled, randomized, parallel-group, multicenter study of the safety and efficacy of JZP385 in the treatment of adult participants with moderate to severe ET.
- Trial name
- NCT05122650
- Testing
- JZP385
- Where
- 73 sites in United States, Germany and 2 more
- Volunteers
- 420 people
- Sponsor
- Jazz Pharmaceuticals
Parkinsonian Syndrome, Parkinson Disease(PD)
A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
This is a multicenter, open-label, non-controlled, non-randomized, phase 3 clinical study to compare the SPECT findings after a single IV administration of DaTSCAN™ ioflupane (123I) injection for patients with a clinical…
- Conditions
- Parkinsonian Syndrome, Parkinson Disease(PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP)
- Trial name
- NCT04193527
- Testing
- DaTSCAN™ Ioflupane (123I) Injection
- Where
- 10 sites in China
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Essential Tremor, Parkinson's Disease
Compare Rates of Agreement Between Clinical Diagnosis and Visual Assessment of DaTscan™ Images in Non-Caucasian and Caucasian Subjects With Parkinson's Disease (PD) or Essential Tremor (ET)
The primary objective of this study is to determine if the diagnostic performance of DaTscan™ single photon emission computed tomography (SPECT) imaging is different in non-Caucasian subjects compared with Caucasian subjects with…
- Trial name
- NCT01952678
- Testing
- DaTscan™ - Non-Caucasian Participants, DaTscan™ - Caucasian Participants
- Where
- United States
- Volunteers
- 204 people
- Sponsor
- GE Healthcare
Essential Tremor
A Phase 2 RCT Study of CX-8998 for Essential Tremor
This is a multicenter, double-blind, placebo-controlled, parallel-group study consisting of a screening period of up to 4 weeks (with the exception of participants on primidone at baseline who will be allowed 6 weeks of screening…
- Trial name
- NCT03101241
- Testing
- CX-8998
- Where
- 22 sites in United States
- Volunteers
- 95 people
- Sponsor
- Jazz Pharmaceuticals
Essential Tremor
A Clinical Trial of PRAX-944 in Participants With Essential Tremor
This is a 2-part clinical trial to evaluate the efficacy, safety, and tolerability of 40 and 120 mg oral PRAX-944 compared to placebo in the treatment of adults with essential tremor.
- Trial name
- NCT05021978
- Testing
- Part A: 20 and 40 mg PRAX-944, Part B: 120 mg PRAX-944
- Where
- 9 sites in United States, Australia and 1 more
- Volunteers
- 24 people
- Sponsor
- Praxis Precision Medicines
Movement Disorders, Parkinson Disease
A Post-Market Study Evaluating the Safety of Infinity DBS System With MR Conditional Labeling
The Infinity MRI PMCF was conducted as an international, multicenter, observational, prospective, single-arm, post-market clinical follow-up (PMCF) study.
- Conditions
- Movement Disorders, Parkinson Disease, Essential Tremor, Tremor
- Trial name
- NCT03884231
- Testing
- Infinity DBS System with MR Conditional labelling
- Where
- 16 sites in United States, France and 3 more
- Volunteers
- 74 people
- Sponsor
- Abbott Medical Devices
Essential Tremor
Study to Evaluate SAGE-324 in Participants With Essential Tremor
The primary purpose of this study is to evaluate the dose-response relationship of different doses of SAGE-324 on upper extremity tremor in participants with essential tremor (ET) in the monotherapy cohort.
- Trial name
- NCT05173012
- Testing
- SAGE-324
- Where
- 51 sites in United States
- Volunteers
- 146 people
- Sponsor
- Sage Therapeutics
Essential Tremor
A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor
The primary purpose of this study is to evaluate the long-term safety and tolerability of SAGE-324 in participants with essential tremor (ET).
- Trial name
- NCT05366751
- Testing
- SAGE-324
- Where
- 38 sites in United States
- Volunteers
- 97 people
- Sponsor
- Sage Therapeutics
Essential Tremor
Cala ONE Device for Essential Tremor
This study evaluates the safety and effectiveness of the Cala ONE device to aid in the symptomatic relief of hand tremors in adult essential tremor subjects.
- Trial name
- NCT02629614
- Testing
- Cala ONE Device
- Where
- 4 sites in United States
- Volunteers
- 93 people
- Sponsor
- Cala Health, Inc.
Parkinson's Disease, Essential Tremor
RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR)
The purpose of this study is to assess the recharge feature of the Activa RC System in patients who are receiving Deep Brain Stimulation (DBS) for Parkinson's Disease (PD), Essential Tremor (ET), or dystonia.
- Conditions
- Parkinson's Disease, Essential Tremor, Dystonia
- Trial name
- RECHARGE (NCT00998660)
- Testing
- Activa RC
- Where
- 11 sites in United States, Austria and 4 more
- Volunteers
- 100 people
- Sponsor
- MedtronicNeuro
Essential Tremor of the Upper Limbs
Botulinum Toxin A to Treat Arm Tremor
The objective of this study is to assess the efficacy and safety of a single, kinematic-analysis-based intramuscular injection of NT 201, compared with placebo, in moderate to marked essential tremor of the upper limb.
- Trial name
- NCT02207946
- Testing
- IncobotulinumtoxinA
- Where
- 6 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Merz Pharmaceuticals GmbH
Essential Tremor
Evaluate SAGE-547 in Participants With Essential Tremor
Stage 1 is a double-blind, proof-of-concept study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SAGE-547 Injection in male and female participants with essential tremor in the upper limb.
- Trial name
- NCT02277106
- Testing
- SAGE-547
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Sage Therapeutics
Essential Tremor
A Pilot Study of the Cala ONE Device for Essential Tremor
Prospective, multi-center, randomized, controlled study designed to evaluate safety and repeatable effectiveness. Subjects will be randomized 2:1:1 to transcutaneous afferent patterned stimulation (TAPS), sham, or 'no…
- Trial name
- EXCITE (NCT03152136)
- Testing
- Cala ONE device
- Where
- 4 sites in United States
- Volunteers
- 62 people
- Sponsor
- Cala Health, Inc.
Tremor, Action Tremor
Deep Brain Stimulation (DBS) for the Suppression of Tremor
The purpose of the proposed study is to demonstrate the safety and efficacy of the ANS Totally Implantable Deep Brain Stimulation System in the VIM nucleus of the thalamus implanted for the treatment of tremor due to essential…
- Conditions
- Tremor, Action Tremor, Essential Tremor, Tremor, Limb
- Trial name
- NCT02087046
- Testing
- ANS Totally Implantable Deep Brain Stimulation System
- Where
- 12 sites in United States
- Volunteers
- 127 people
- Sponsor
- Abbott Medical Devices
Essential Tremor
A Clinical Study to Evaluate CAD-1883 in Essential Tremor
This is an open-label study designed to evaluate the safety, tolerability and efficacy of CAD-1883, a positive allosteric modulator of the SK channel, administered twice daily orally to adult patients with ET.
- Trial name
- NCT03688685
- Testing
- CAD-1883
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- Cadent Therapeutics
Essential Tremor, Parkinson's Disease
Evaluation of the Infinity Deep Brain Stimulation Electrode Screening Mode Tool
The objective of this clinical investigation is to characterize the clinical performance of Abbott's Clinician Programmer Electrode Screening Mode tool (InformityTM tool) in programming InfinityTM deep brain stimulation (DBS)…
- Trial name
- EVIDENT (NCT03794661)
- Testing
- Clinician programmer electrode screening mode tool
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Abbott Medical Devices